Immunomedics, Inc. (IMMU) Presents Epratuzumab's Mechanism of Action in Systemic Lupus Erythematosus
6/13/2013 8:46:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MADRID, Spain, June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, mediates the reduction of select proteins on the surface of B cells via a process known as trogocytosis, and that such reduction could modulate B-cell activities.Results from this study were presented by Edmund A. Rossi, Ph.D., Executive Director, Recombinant Technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by